All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drchloevic on TikTok · 36s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drchloevic's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hey guys, today is shot day and this is my third shot.
  2. 0:04So we're heading into week three of being on compounds in my blue tide.
  3. 0:08Usually I have no side effects, but maybe a little bit of mild noir on the day of the shot.
  4. 0:13And my appetite suppression usually doesn't kick in for about 24 to 48 hours.
  5. 0:18I take my shot in the morning and I take it before breakfast and I don't seem to have any issues with that.
  6. 0:25I am only taking 25 units so I'm sure as I move up I might experience some more side effects.
  7. 0:31But guys I'm seven pounds down. I'm so excited. You have any questions?

@drchloevic's semaglutide health claims, fact-checked

Drchloevic

TikTok creator

19.5K viewsWatch on TikTok

Quick answer

The creator is self-reporting week three of compounded tirzepatide at a dose she describes as '25 units,' with mild injection-day nausea and delayed appetite suppression onset of 24 to 48 hours. These experiences are broadly consistent with tirzepatide's known pharmacodynamic profile, but the unit-based dose description cannot be clinically interpreted without knowing the compounded vial concentration. Seven pounds of early weight loss is plausible but likely reflects mixed fat and fluid loss at this stage.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @drchloevic's semaglutide health claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@drchloevic's semaglutide health claims, fact-checked" from Drchloevic. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is self-reporting week three of compounded tirzepatide at a dose she describes as '25 units,' with mild injection-day nausea and delayed appetite suppression onset of 24 to 48 hours.

The reason this review is not generic is the source wording and the canonical claim label "glp1 healthy lifestyle changes inflammation healthandwellness." In this clip, the useful excerpt is: "Hey guys, today is shot day and this is my third shot." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

SURMOUNT-1 (Jastreboff et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is self-reporting week three of compounded tirzepatide at a dose she describes as '25 units,' with mild injection-day nausea and delayed appetite suppression onset of 24 to 48 hours.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is self-reporting week three of compounded tirzepatide at a dose she describes as '25 units,' with mild injection-day nausea and delayed appetite suppression onset of 24 to 48 hours. These experiences are broadly consistent with tirzepatide's known pharmacodynamic profile, but the unit-based dose description cannot be clinically interpreted without knowing the compounded vial concentration. Seven pounds of early weight loss is plausible but likely reflects mixed fat and fluid loss at this stage.
  • Tirzepatide has a half-life of roughly five days, so steady-state appetite suppression effects take several weeks to accumulate, making early variation in onset timing normal.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found nausea in approximately 25-30% of participants at lower tirzepatide doses, supporting the creator's mild side effect report as consistent with the data.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Tirzepatide has a half-life of roughly five days, so steady-state appetite suppression effects take several weeks to accumulate, making early variation in onset timing normal.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found nausea in approximately 25-30% of participants at lower tirzepatide doses, supporting the creator's mild side effect report as consistent with the data.
  • Compounded tirzepatide is not FDA-approved and lacks the clinical trial safety and efficacy data that applies to brand-name Mounjaro and Zepbound. The FDA issued explicit warnings about compounded GLP-1 products in 2024.
  • Dosing compounded peptides in 'units' without stating vial concentration is clinically meaningless and risks misinterpretation. Patients should always confirm their dose in milligrams with their prescriber.
  • Early weight loss of several pounds in the first weeks of GLP-1 therapy often reflects fluid shifts and glycogen depletion, not purely fat loss. More meaningful body composition data emerges around the 12-week mark.
  • Gastrointestinal side effects with tirzepatide are dose-dependent. SURMOUNT-1 showed significantly higher rates of nausea and vomiting at 10 mg and 15 mg compared to the 2.5 mg starting dose.
  • Morning versus evening injection timing for tirzepatide is not clinically standardized, but some prescribers recommend evening dosing to allow peak nausea periods to occur during sleep.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drchloevic actually say?

She's three weeks into compounded tirzepatide, taking "25 units" subcutaneously on shot day, before breakfast, in the morning. Her reported side effects are minimal: "maybe a little bit of mild nausea on the day of the shot," with appetite suppression hitting roughly 24 to 48 hours post-injection. She's down seven pounds and framing this as a straightforward, low-drama start. She also refers to the medication as "compounds in my blue tide," which appears to be a transcription artifact for compounded tirzepatide.

The claims here are experiential rather than medical, which is mostly fine for a personal account. But the "25 units" language creates a real problem for anyone watching and trying to interpret their own prescription, and her framing of side effects as mild and expected deserves some scrutiny against what the literature actually shows.

Does the science back this up?

Her reported timeline for appetite suppression is plausible. Tirzepatide's dual GIP and GLP-1 receptor agonism produces appetite reduction through central and peripheral pathways, and anecdotal onset variation in the first weeks is consistent with the pharmacokinetic profile. The drug has a half-life of roughly five days, so steady-state effects take several weeks to accumulate.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed mean weight loss of 20.9% at 72 weeks with 15 mg tirzepatide. Early weight loss in the first three weeks at lower doses, like the seven pounds she reports, is biologically possible, though some of that is likely water weight and glycogen depletion rather than fat loss, particularly this early. Nausea as the primary early side effect is consistent with the SURMOUNT-1 adverse event profile, where gastrointestinal symptoms were most common during dose escalation.

What did they get wrong (or right)?

The biggest issue is the "25 units" framing. Compounded tirzepatide is typically prepared in a concentration of 5 mg/mL or similar, meaning units are not a universal measure here. Unlike insulin, where units have a standardized meaning, peptide doses measured in units are concentration-dependent. Saying "25 units" without stating the concentration of the vial tells viewers essentially nothing clinically useful, and worse, it could lead someone to assume their prescription works the same way. This is a real harm vector.

She gets credit for not overclaiming. She doesn't say tirzepatide cured anything, she doesn't recommend a dose to viewers, and she openly notes side effects may worsen at higher doses. That kind of epistemic humility is rarer than it should be in GLP-1 content. The morning injection timing before breakfast is not contraindicated, though some clinicians suggest evening dosing to sleep through peak nausea.

What should you actually know?

Compounded tirzepatide is not the same as Mounjaro or Zepbound. The FDA has repeatedly flagged concerns about compounded GLP-1 products, including dosing inconsistencies and sterility questions. In 2024, the FDA issued a statement warning that compounded tirzepatide products lack the clinical trial data that supports the brand-name versions.

The "units" problem is not trivial. A 2023 case series in Obesity Medicine documented dosing errors in patients self-administering compounded peptides partly because of unit-versus-milligram confusion. Anyone on a compounded GLP-1 should confirm their dose in milligrams with the prescribing clinician, not units, and should verify the concentration printed on their vial.

Seven pounds in three weeks sounds exciting, and it may well be real progress. But early rapid weight loss on GLP-1 therapy often includes fluid shifts. The more meaningful number will come at the 12-week mark.

The bottom line

This is a personal progress video, not a medical tutorial, and it should be evaluated as such. The creator's experience is genuine and her side effect report is consistent with the pharmacology. But the unit-based dosing language is genuinely confusing and should not be replicated. If you are on a compounded tirzepatide protocol and your prescription is written in units, call your provider and ask for the milligram equivalent and vial concentration before your next injection.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Drchloevic · TikTok creator

19.5K views on this video

Healthy lifestyle changes #inflammation #healthandwellness #weightlossjouney #glp1community #semiglutide #glp1forweightloss #SemaglutideJourney #AnxietyRelief #SemaglutideResults

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide has a half-life of roughly five days, so steady-state?

Tirzepatide has a half-life of roughly five days, so steady-state appetite suppression effects take several weeks to accumulate, making early variation in onset timing normal.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) found nausea in approximately?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found nausea in approximately 25-30% of participants at lower tirzepatide doses, supporting the creator's mild side effect report as consistent with the data.

What does the video say about compounded tirzepatide?

Compounded tirzepatide is not FDA-approved and lacks the clinical trial safety and efficacy data that applies to brand-name Mounjaro and Zepbound. The FDA issued explicit warnings about compounded GLP-1 products in 2024.

Dosing compounded peptides in 'units' without stating vial concentration is clinically meaningless and risks misinterpretation. Patients should always confirm their dose in milligrams with their prescriber?

Dosing compounded peptides in 'units' without stating vial concentration is clinically meaningless and risks misinterpretation. Patients should always confirm their dose in milligrams with their prescriber.

What does the video say about early weight loss of several pounds in the first weeks?

Early weight loss of several pounds in the first weeks of GLP-1 therapy often reflects fluid shifts and glycogen depletion, not purely fat loss. More meaningful body composition data emerges around the 12-week mark.

What does the video say about gastrointestinal side effects with tirzepatide?

Gastrointestinal side effects with tirzepatide are dose-dependent. SURMOUNT-1 showed significantly higher rates of nausea and vomiting at 10 mg and 15 mg compared to the 2.5 mg starting dose.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Drchloevic, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.